Question 1

What exactly do the RSV non-structural proteins target?

Accepted Answer

NS1 and NS2 act at several points in the interferon pathway, degrading or sequestering signalling intermediates including STAT2 and disrupting RIG-I and MAVS function. NS1 has also been reported to enter the nucleus and shape transcriptional programmes. Most doctoral projects focus on one interaction and characterise it in depth rather than surveying all reported targets.

Question 2

How are recombinant viruses lacking these genes produced?

Accepted Answer

Reverse genetics systems rescue infectious virus from a full-length antigenomic plasmid together with support plasmids expressing the polymerase complex. Removing an accessory gene yields a matched mutant for comparison. Rescue efficiency varies, so candidates budget several attempts and verify recovered stocks by sequencing before any phenotyping begins.

Question 3

Which culture systems give physiologically meaningful readouts?

Accepted Answer

Primary human bronchial epithelial cells differentiated at the air-liquid interface reproduce ciliated and secretory architecture and give far more relevant infection kinetics than immortalised monolayers. Airway organoids and precision-cut lung slices extend this further. Donor variation is substantial, so parallel donors and clear replication structure are essential.

Question 4

How should interferon-stimulated gene data be analysed?

Accepted Answer

Interferon signatures shift sharply with inoculum, timing, and donor background, so matched multiplicity and synchronised harvest points matter more than deep sequencing. Analysis typically pairs targeted quantitative panels with transcriptome-wide profiling, and interpretation should separate induction magnitude from kinetic delay, which are distinct evasion phenotypes.

Question 5

What containment and ethics steps apply to this work?

Accepted Answer

Work with infectious virus normally requires containment level two facilities, documented decontamination, and institutional biosafety approval before starting. Projects using primary human cells need donor consent documentation and ethics clearance, and neonatal animal models require separate approval. Building this paperwork into the first months avoids stalled benchwork later.

Question 6

How does evasion research connect to vaccine development?

Accepted Answer

Attenuating the accessory genes has been explored as a way to build live candidates that provoke a stronger interferon response while replicating less. Understanding which host pathways are suppressed also guides adjuvant selection and helps interpret immune profiles from candidate trials. Doctoral projects usually address one mechanistic link rather than vaccine efficacy itself.

Question 7

What prior background helps most before starting?

Accepted Answer

Sterile cell culture practice, quantitative virology including plaque and focus assays, and comfort with quantitative reverse transcription methods form the core. Familiarity with innate immune signalling architecture and with scripting for sequencing analysis shortens the start-up phase considerably. Gaps in reverse genetics specifically can be closed through structured early training.

Microbiology

Microbiology

Research Frontiers in Respiratory Syncytial Virus Immune Evasion